Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma

The Key Multiple Myeloma Companies in the market include - Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others.

The Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

DelveInsight's "Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast [https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Multiple Myeloma Market Report:

*
The Multiple Myeloma market size was valued approximately USD ~21 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In March 2025, The HealthTree Foundation has launched a cutting-edge AI-powered Personalized Clinical Trial Finder designed to assist multiple myeloma (MM) patients in locating suitable clinical trials. Now part of the HealthTree Cure Hub Registry, this advanced tool leverages artificial intelligence to analyze individual medical histories, making the trial matching process more precise and efficient.

*
In January 2025, Sanofi, a pharmaceutical company based in France, has announced positive results from its Phase III IRAKLIA trial evaluating Sarclisa (isatuximab) as a treatment option for multiple myeloma (MM). The study enrolled 531 adult MM patients who had previously undergone at least one line of therapy, including treatment with lenalidomide and a proteasome inhibitor, across 252 international sites. The trial achieved its co-primary endpoints with Sarclisa-administered subcutaneously using an on-body delivery system (OBDS)-in combination with pomalidomide and dexamethasone (Pd).

*
In September 2024, Johnson & Johnson has shared results from its Phase III CARTITUDE-4 clinical trial, revealing that its cell therapy, CARVYKTI (ciltacabtagene autoleucel), led to a significant improvement in overall survival for patients with multiple myeloma. The study included patients who had received at least one prior line of treatment, including a proteasome inhibitor (PI). In a randomized trial design, CARVYKTI was evaluated against standard treatment regimens such as pomalidomide, bortezomib, and dexamethasone (PVd), or daratumumab, pomalidomide, and dexamethasone (DPd).

*
In August 2024, Opna Bio, a Swiss biopharmaceutical firm, has initiated dosing in its Phase I clinical trial of OPN-6602, an EP300/CBP bromodomain inhibitor being developed for the treatment of multiple myeloma. The study aims to recruit up to 130 patients with relapsed or refractory multiple myeloma at various sites across the United States. The first dose was administered at The START Center for Cancer Research in Grand Rapids, Michigan.

*
In April 2024, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) announced that the U.S. Food and Drug Administration (FDA) approved Abecma Registered (idecabtagene vicleucel; ide-cel) on April 4, 2024, for adults with relapsed or refractory multiple myeloma who have received at least two previous lines of therapy. These prior treatments must include an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. This expanded approval, supported by the KarMMa-3 trial, enables earlier use of Abecma in patients who have been exposed to all three therapy classes (triple-class exposed). Abecma is delivered as a single infusion, with a newly recommended dose range of 300 to 510 x 10 CAR-positive T cells.

*
In 2023, the total market size for multiple myeloma in the US was approximately USD 14.3 billion, with expectations of growth by 2034.

*
In March 2024, Johnson & Johnson announced that the US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended CARVYKTI for treating adult patients with Relapsed/Refractory Multiple Myeloma (RRMM) who have undergone at least one prior therapy, including a proteasome inhibitor and an IMiD, and are refractory to lenalidomide.

*
In the 4L+ setting, approved CAR-T therapies (ABECMA and CARVYKTI) were projected to generate approximately USD 828 million in the US in 2023, with this figure expected to increase as new CAR-T therapies gain approval throughout the forecast period.

*
In 2023, the total number of incident cases of multiple myeloma in the 7MM was approximately 75,000, and this figure is expected to grow throughout the forecast period.

*
In the 7MM, the United States recorded the highest number of incident cases of multiple myeloma, followed by the EU4 nations and the UK.

*
In 2023, Germany had the highest number of incident cases of multiple myeloma among the EU4 countries and the UK, while Spain had the lowest.

*
Multiple myeloma is more prevalent in males than in females, with over 50% of cases in the United States being diagnosed in men.

*
Key Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others

*
Key Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others

*
The Multiple Myeloma epidemiology based on gender analyzed that males are affected more in case of Multiple Myeloma as compared to females.

*
The Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

Multiple Myeloma Overview

Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. In multiple myeloma, abnormal plasma cells multiply uncontrollably and produce an excess of abnormal antibodies, which can cause damage to the bones and other organs. Common symptoms include bone pain, weakness, fatigue, frequent infections, and anemia.

Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/multiple-myeloma-market [https://www.delveinsight.com/report-store/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Multiple Myeloma

*
Prevalent Cases of Multiple Myeloma by severity

*
Gender-specific Prevalence of Multiple Myeloma

*
Diagnosed Cases of Episodic and Chronic Multiple Myeloma

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast [https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple Myeloma Therapies and Key Companies

*
CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine

*
Mezigdomide (CC-92480): Bristol Myers Squibb

*
Linvoseltamab (REGN5458): Regeneron

*
Venetoclax: AbbVie and Roche

*
ABBV 383: AbbVie

*
Talquetamab: Janssen Pharmaceutical

*
Linvoseltamab: Regeneron Pharmaceuticals

*
Descartes 08: Cartesian Therapeutics

*
Lenalidomide: Alliance Foundation Trials, LLC.

*
Selinexor: US Oncology Research

*
Descartes-25: Cartesian Therapeutics

*
Pomalidomide: GlaxoSmithKline

*
TG01: Targovax ASA

*
Cyclophosphamide: Janssen Research & Development

*
AZD0305: AstraZeneca

*
bb2121: Celgene

*
EOS884448: Bristol-Myers Squibb

*
Elranatamab: Pfizer

*
APG-2575: Ascentage Pharma Group Inc.

*
TNB-383B: TeneoOne Inc.

*
PHE885: Novartis

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape [https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Multiple Myeloma Market Strengths

*
Emerging therapies such as CAR-T cell and monoclonal antibodies showing promising results in treating multiple myeloma patients and expected to drive the growth of market. It also amends the treatment landscape in cancer due to its high specificity and minimal side effect profile.

Multiple Myeloma Market Opportunities

*
BCMA-targeting therapies are expected to result in noteworthy revenues due to premium pricing and clinical benefit in heavily pretreated patients.

Scope of the Multiple Myeloma Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Multiple Myeloma Companies: Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others

*
Key Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), Mezigdomide (CC-92480), Linvoseltamab (REGN5458), Venetoclax, ABBV 383, Talquetamab, Linvoseltamab, Descartes 08, Lenalidomide, Selinexor, Descartes-25, Pomalidomide, TG01, Cyclophosphamide, AZD0305, bb2121, EOS884448, Elranatamab, APG-2575, TNB-383B, PHE885, and others

*
Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies

*
Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Multiple Myeloma Unmet Needs, KOL's views, Analyst's views, Multiple Myeloma Market Access and Reimbursement

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2020-2034)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market Drivers

16. Multiple Myeloma Market Barriers

17. Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-myeloma-market-set-to-grow-substantially-through-2034-delveinsight-projects-johnson-johnson-innovative-medicine-bristol-myers-squibb-regeneron-abbvie-and-roche-janssen-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.